Navigation Links
Harmonizing Biobank Research Conference in 2009
Date:12/18/2008

How can we maximise the value and use of epidemiological biobanks by harmonising efforts between countries? This is the theme of a conference being held on the 25-27th March in Brussels, Belgium.

Co-organised by PHOEBE (Promoting Harmonisation of Epidemiological Biobanks), P3G (Public Population Project in Genomics) and BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), the conference will cover two overarching themes: Using Biobanks and Maximising the Use of Biobanks.

Recent years have witnessed intense activities targeted towards building a harmonised network of biobanks to support large-scale genomics. Substantial investments in biobanking will continue to evolve and serve large European bioscience, and bioscience worldwide. Many countries envision that biobanks will become a part of their medical research and health care infrastructure. An already impressive number of funded initiatives are working on critical building blocks of the harmonisation and infrastructure agendas. These projects span population-based and special populations (PHOEBE, GENOMEUTWIN, ENGAGE, EUROSPAN, GEHA, PHIME, DIOGENES, etc), disease-specific and tissue banks (DANUBIOBANK, GenOSept, IMPACTS, HYPERGENES, CCPRB, GENPI-ENTB2, ORPHANET, EUROBONET, CONTICANET, TRANSBIG, GENOMEL, etc), infrastructure building (BBMRI, INSTRUCT, INFRAFRONTIER, EATRIS, EATRIN, ELIXIR), harmonisation tools and technologies (MOLPAGE, BIOSAPIENS, Gen2PHEN, MOLTOOLS, ReaDNA, INFOBIOMED, SYMBIOMATICS, etc) and ELSI, society and public health (GeneBanC, Priviledged, PHGEN, TISS.EU, etc). The collective output from these projects have already made significant inroads in biobanking science and in the science of biobanking. This includes work related to identifying key issues, design and management of biobanks, SOPs for sample handing, cataloguing and comparing information, coordinated development of compatible bioinformatics, including systems for access across biobanks of d
'/>"/>

Contact: Elisabeth Shaw
elisabeth.shaw@fhi.no
Norwegian Institute of Public Health
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Manchester clears first hurdle in €170 million biobank building boom
2. F-MARC funds more soccer and health research
3. No quick or easy technological fix for climate change, researchers say
4. Researchers find natures shut-off switch for cellulose production
5. Researchers compile molecular manual for 100s of inherited diseases
6. VCU survey: US public supports genetic research, testing and government spending on research
7. Life Sciences Discovery Fund awards health research program grants
8. Pitt researchers create non-toxic clean-up method for potentially toxic nano materials
9. Researchers identify new anti-tumor gene
10. MU researcher identifies possible genetic causes of borderline personality disorder
11. UAF researchers to present at AGU press briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)UVALDE Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist at the Texas AgriLife Research and Extension Center in Uvalde, has been investigating ways to help vegetable plants make a les
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 1SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 3Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 1Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 2Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2
...archers at MIT recently found an elegant solution ...anics: why water doesn,t soak into soil at an even... fluid flowing downward. , Scientists call these...or their formation has to do with the surface tens... other medium). Knowing how to account for this ph...
...ORD/SOMERVILLE, Mass. -- A new study from the psyc...hen dieters eliminate carbohydrates from their mea...ks than when they reduce calories, but maintain ca... cognition skills returned to normal. , "This stu...immediate impact on cognitive behavior," explains ...
...ANTONIO Douglas Easton, Ph.D., whose internationa...atterns and causes of the BRCA1 and BRCA2 gene mut...ancer, has been selected to receive the inaugural ...tstanding Investigator Award in Breast Cancer Rese... the Cure, recognizes an investigator whose novel ...
Other Biology News:MIT researchers explain mystery of gravity fingers 2Low-carb diets can affect dieters' cognition skills 2Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research 2
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ing RNAi Industry through,Addition of Important an...P, PALO ALTO, Calif., April 9, 2008 Intradigm Co...c RNA interference (RNAi),therapeutics, today anno...ty (IP) covering certain efficacy-enhancing struct...m the University of Massachusetts Medical,School. ...
...ronext Brussels: THR), a biotechnology company foc..., announces today that it has completed,patient en...y purpose of,this study is to evaluate the safety ...nistered intravenously to acute stroke patients,be... stroke., MITI IV (Microplasmin in Treatment of I...
...Nasdaq: DNDN ) today announced that it has comple...ering of 8.0 million shares of its common,stock an... its common,stock. Net proceeds received by Dendre...Markets LLC served as sole placement agent for the...o previously effective shelf,registration statemen...
Other Biology Technology:Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 2Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 3Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 4ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2
Rabbit Anti-Human Rab1A Antibody, Unconjugated from Spring Bioscience
Rat Anti-Acetyl Salicylic Acid conjugated Acetyl Salicylic Acid Polyclonal Antibody, Unconjugated from Cell Sciences
Beadlyte® Human IgE Standard from Upstate
...uct Mouse monoclonal [SPM278] to 67kD Laminin Rec...inoma N592 live cells (Human). Reactivity / Speci... other species. Background Information Laminin, ...e, displays multiple biological activities which a...
Biology Products: